Search Results

Viewing Page 1 of 1 | Showing results 1 - 5 of 5

A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis (CLARITY) (AIN457A2326)

Participants are needed for this UC Irvine Health clinical study of secukinumab efficiacy in moderate to severe plaque psoriasis.
Natasha Mesinkovska, MD, PhD

UC Irvine Dermatology Clinical Research Center, 1001 Hewitt Hall, Irvine, CA 92697

A Phase 2, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety, tolerability, and efficacy of KD025 in adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy

Participants are needed for this UC Irvine Health clinical study of KD025 safety, tolerability and efficiacy for cases of moderate to severe plaque...
Natasha Mesinkovska, MD, PhD

At the UC Irvine campus:
Dermatology Clinical Research Center
843 Health Science Road
Hewitt Hall, Room 1001
Irvine, CA 92697

A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients - RegiSONIC

A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell...
Kenneth Linden, MD, PhD

Dermatology Clinical Research Center, University of California, Irvine, 1001 Hewitt Hall, Irvine CA 92697

Gottschalk Medical Plaza, 2100 Medical Plaza Drive, Irvine, CA 92697

Chao Family Comprehensive Cancer Center, 101 The City Drive, Orange CA 92686

Minimally invasive holmium: YAG laser blepharoplasty

Brian J. Wong, MD, PhD

Beckman Laser Institute and Medical Clinic